CompletedNot Applicable

Preliminary Effectiveness of Remotely Monitored Blood Alcohol Concentration Device as Treatment Modality

United States96 participantsStarted 2020-06-29

Plain-language summary

State the scientific aim(s) of the study, or the hypotheses to be tested. The purpose of the current study is to evaluate the usage and acceptability of the Soberlink's blood alcohol concentration (BAC) unit in collaboration with Aware treatment to assess increased sobriety within patients suffering from alcohol use disorder (AUD). The specific AIMS will be: 1. To determine the effectiveness of Soberlink's ability to increase abstinence 2. To evaluate the impact of Soberlink's device on the participant based on their quality of health and sobriety. 3. To evaluate the extent to which need for higher levels of follow-up care and treatment is reduced for individuals who have had access to the Soberlink device.

Who can participate

Age range21 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * are at least 21 years old, * currently enrolled at Aware In home treatment, * Primary or secondary DSM-5 diagnosis of alcoholism use disorder (AUD). Exclusion Criteria: * Current suicide or homicide risk, * meet criteria for DSM-IV current psychotic disorder, or bipolar disorder, * does not have phone access with text message capabilities * Unable to read or understand English, * Unable to complete the study because of anticipated incarceration or move, * Life-threatening or unstable medical problems, * No course of current or pending legal action, * Soberlink results being used for child custody or legal circumstance.

What they're measuring

Alcohol Time Line Follow Back (TLFB)

Timeframe: up to 24 weeks

Trial details

NCT IDNCT04380116

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-05-01

Results submitted2023-04-27